Here are Top Health stories of the day
Duty of Medical Council to ensure that doctors do not indulge in offences: Madras HC
Holding that it is the duty of the Tamil Nadu Medical Council to take appropriate action to ensure that doctors did not indulge offences, the Madras High Court has recently slammed a doctor for issuing a false medical certificate to a person, who used the same for getting anticipatory bail.
As the court was informed that disciplinary proceedings would be initiated against the doctor by the Tamil Nadu Medical Council, the court clarified that issuing false certificates for the purpose of leave was an offence, reports The Hindu.
For more details, check out the full story on the link below:
Duty Of Medical Council To Ensure That Doctors Do Not Indulge In Offences: Madras HC
TN Health Minister inaugurates country's first 3D eye surgery facility in Chennai
Haryana nearly doubles up MD, MS fee structure for private medical colleges this year
The fees for MD/MS courses in the private medical colleges of Haryana has been hiked by almost 100 per cent, according to the recent notification issued by the Medical Education & Research Department.
In the notification dated November 16, 2021, the Haryana Government has released the new fee structure of MD/MS courses, MBBS, B.Sc. Nursing/Post Basic B.Sc. Nursing/M.Sc. Nursing, BPT Courses and ANM/GNM/MPHW(M) Course running under Government Institutions and private institutions affiliated to Pt. B.D. Sharma UHS, Rohtak.
For more details, check out the full story on the link below:
Haryana Nearly Doubles Up MD, MS Fee Structure For Private Medical Colleges This Year
Delhi: Resident doctors to go on indefinite strike from November 22
The resident doctors of Delhi's Hindu Rao Hospital have intensified their protests and are planning to go on indefinite strike from November 22 over the non-payment of salaries for the past three months.
The 300-member Resident Doctors' Association (RDA) of the hospital has recently staged a peaceful protest demanding the immediate payment of the pending salaries.
For more details, check out the full story on the link below:
Delhi: Resident Doctors To Go On Indefinite Strike From November 22
Novartis gets CDSCO panel nod to conduct phase 3 study of anti-cancer drug Asciminib
In a significant development, major drug-maker Novartis has got a go ahead from the Subject Expert Committee (SEC) functional under the Central Drugs Standard Control Organization (CDSCO) to conduct a Phase 3 clinical trial of Asciminib, a Tyrosine Kinase Inhibitor (TKI) for the treatment of Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase.
This came in wake of the Phase III clinical trial protocol presented by Novartis at the recent SEC meeting for Oncology and Haematology.
For more details, check out the full story on the link below:
Novartis Gets CDSCO Panel Nod To Conduct Phase 3 Study Of Anti-Cancer Drug Asciminib
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.